Toward in situ tissue engineering: Chemokine-guided stem cell recruitment

Trends in Biotechnology

Volumn 32, Issue 9, 2014, Pages 483-492

  Andreas, Kristin ^a   Sittinger, Michael ^a   Ringe, Jochen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CCL25; Chemokines; In situ tissue engineering; Mesenchymal stem cells; Mobilization and homing; Regenerative medicine

Indexed keywords

PEPTIDES; STEM CELLS; TISSUE ENGINEERING;

CCL25; CHEMOKINES; MESENCHYMAL STEM CELL; MOBILIZATION AND HOMING; REGENERATIVE MEDICINE; SITU TISSUE ENGINEERINGS;

CELL CULTURE;

ALGINIC ACID; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CHITOSAN; COLLAGEN; FIBRIN; GELATIN; GLYCOSAMINOGLYCAN; HEPARIN; HYALURONIC ACID; LIPID; MICROSPHERE; NANOPARTICLE; PEPTIDE; POLYELECTROLYTE; POLYGLACTIN; POLYGLUTAMIC ACID; POLYMER; STROMAL CELL DERIVED FACTOR 1; THYMUS EXPRESSED CHEMOKINE; TISSUE SCAFFOLD; UNCLASSIFIED DRUG;

CELL TYPE; CHEMOTAXIS; CHEMOTAXIS ASSAY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; MESENCHYMAL STEM CELL; MICROELECTROMECHANICAL SYSTEM; MICROFLUIDICS; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; STEM CELL; STEM CELL HOMING; STEM CELL MOBILIZATION; STEM CELL RESEARCH; THYMUS; TISSUE ENGINEERING; TISSUE REGENERATION; MEDICAL RESEARCH; METABOLISM; PHYSIOLOGY; PROCEDURES; TRENDS;

BIOMEDICAL RESEARCH; CHEMOKINES; GUIDED TISSUE REGENERATION; STEM CELLS;

EID: 84906322022     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2014.06.008     Document Type: Review

References (91)

1. Shi C. Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells. Immunology 2012, 136:133-138.
2. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012, 10:709-716.
3. Anders H.J., et al. Pathomechanisms: homeostatic chemokines in health, tissue regeneration, and progressive diseases. Trends Mol. Med. 2014, 20:154-165.
4. Ringe J., et al. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J. Cell. Biochem. 2007, 101:135-146.
5. Sordi V., et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005, 106:419-427.
6. Honczarenko M., et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006, 24:1030-1041.
7. - progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev. 2005, 14:329-336.
8. Rüster B., et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006, 108:3938-3944.
9. Ponte A.L., et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007, 25:1737-1745.
10. Bara J.J., et al. Bone marrow-derived mesenchymal stem cells change phenotype following in vitro culture: implications for basic research and the clinic. Stem Cells 2014, 32:1713-1723.
11. Binger T., et al. Migration potential and gene expression profile of human mesenchymal stem cells induced by CCL25. Exp. Cell Res. 2009, 315:1468-1479.
12. Kalwitz G., et al. Chemokine profile of human serum from whole blood: migratory effects of CXCL-10 and CXCL-11 on human mesenchymal stem cells. Connect. Tissue Res. 2010, 51:113-122.
13. Chamberlain G., et al. Mesenchymal stem cells exhibit firm adhesion, crawling, spreading and transmigration across aortic endothelial cells: effects of chemokines and shear. PLoS ONE 2011, 6:e25663.
14. Liu H., et al. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1alpha in MSCs. Biochem. Biophys. Res. Commun. 2010, 401:509-515.
15. Rankin S.M. Chemokines and adult bone marrow stem cells. Immunol. Lett. 2012, 145:47-54.
16. Wynn R.F., et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004, 104:2643-2645.
17. Stich S., et al. Gene expression profiling of human mesenchymal stem cells chemotactically induced with CXCL12. Cell Tissue Res. 2009, 336:225-236.
18. Liu L., et al. Hypoxia-inducible factor-1alpha is essential for hypoxia-induced mesenchymal stem cell mobilization into the peripheral blood. Stem Cells Dev. 2011, 20:1961-1971.
19. Vanden Berg-Foels W.S. In situ tissue regeneration: chemoattractants for endogenous stem cell recruitment. Tissue Eng. Part B: Rev. 2014, 20:28-39.
20. Schenk S., et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007, 25:245-251.
21. Sasaki M., et al. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J. Immunol. 2008, 180:2581-2587.
22. Ceradini D.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 2004, 10:858-864.
23. Ceradini D.J., Gurtner G.C. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc. Med. 2005, 15:57-63.
24. Rochefort G.Y., et al. Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells 2006, 24:2202-2208.
25. Abbott J.D., et al. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004, 110:3300-3305.
26. Wang Y., et al. SDF-1alpha/CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. Brain Res. 2008, 1195:104-112.
27. Togel F., et al. Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. Kidney Int. 2005, 67:1772-1784.
28. Kitaori T., et al. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum. 2009, 60:813-823.
29. Hu C., et al. CXCL12/CXCR4 axis promotes mesenchymal stem cell mobilization to burn wounds and contributes to wound repair. J. Surg. Res. 2013, 183:427-434.
30. Zhou S.B., et al. Mechanical stretch upregulates SDF-1alpha in skin tissue and induces migration of circulating bone marrow-derived stem cells into the expanded skin. Stem Cells 2013, 31:2703-2713.
31. Zhang F., et al. Transforming growth factor-beta promotes recruitment of bone marrow cells and bone marrow-derived mesenchymal stem cells through stimulation of MCP-1 production in vascular smooth muscle cells. J. Biol. Chem. 2009, 284:17564-17574.
32. Wang L., et al. Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. Exp. Hematol. 2002, 30:831-836.
33. Pattappa G., et al. CCL5/RANTES is a key chemoattractant released by degenerative intervertebral discs in organ culture. Eur. Cell Mater. 2014, 27:124-136. discussion 136.
34. Zhu J., et al. Fractalkine and CX3CR1 are involved in the migration of intravenously grafted human bone marrow stromal cells toward ischemic brain lesion in rats. Brain Res. 2009, 1287:173-183.
35. Lau T.T., Wang D.A. Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin. Biol. Ther. 2011, 11:189-197.
36. Ratajczak M.Z., et al. A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients. Leukemia 2012, 26:63-72.
37. Jalili A., et al. Complement C1q enhances homing-related responses of hematopoietic stem/progenitor cells. Transfusion 2010, 50:2002-2010.
38. Wu W., et al. The bone marrow-expressed antimicrobial cationic peptide LL-37 enhances the responsiveness of hematopoietic stem progenitor cells to an SDF-1 gradient and accelerates their engraftment after transplantation. Leukemia 2012, 26:736-745.
39. Ratajczak M.Z., et al. The role of sphingosine-1 phosphate and ceramide-1 phosphate in trafficking of normal stem cells and cancer cells. Expert Opin. Ther. Targets 2014, 18:95-107.
40. Karapetyan A.V., et al. Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction. Stem Cells Dev. 2013, 22:1645-1656.
41. Kim C., et al. Ceramide-1-phosphate regulates migration of multipotent stromal cells and endothelial progenitor cells - implications for tissue regeneration. Stem Cells 2013, 31:500-510.
42. Li C., et al. Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. J. Hepatol. 2009, 50:1174-1183.
43. Qiu Y., et al. Mesenchymal stromal cells derived from umbilical cord blood migrate in response to complement C1q. Cytotherapy 2012, 14:285-295.
44. Salanga C.L., Handel T.M. Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp. Cell Res. 2011, 317:590-601.
45. Proudfoot A.E., et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1885-1890.
46. + stem/progenitor cells to bone marrow. Blood 2004, 103:2981-2989.
47. Rueda P., et al. Homeostatic and tissue reparation defaults in mice carrying selective genetic invalidation of CXCL12/proteoglycan interactions. Circulation 2012, 126:1882-1895.
48. Netelenbos T., et al. Differences in sulfation patterns of heparan sulfate derived from human bone marrow and umbilical vein endothelial cells. Exp. Hematol. 2001, 29:884-893.
49. Askari A.T., et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 362:697-703.
50. Chen F.M., et al. Homing of endogenous stem/progenitor cells for in situ tissue regeneration: promises, strategies, and translational perspectives. Biomaterials 2011, 32:3189-3209.
51. Kumamoto T., et al. Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine. Nat. Biotechnol. 2002, 20:64-69.
52. Zhao X., et al. Directed cell migration via chemoattractants released from degradable microspheres. Biomaterials 2005, 26:5048-5063.
53. Singh A., et al. In situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. Biomaterials 2009, 30:5187-5200.
54. Wang Y., Irvine D.J. Engineering chemoattractant gradients using chemokine-releasing polysaccharide microspheres. Biomaterials 2011, 32:4903-4913.
55. Segers V.F., et al. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007, 116:1683-1692.
56. + cell homing to the infarcted heart. Tissue Eng. 2007, 13:2063-2071.
57. Bladergroen B.A., et al. In vivo recruitment of hematopoietic cells using stromal cell-derived factor 1 alpha-loaded heparinized three-dimensional collagen scaffolds. Tissue Eng. Part A 2009, 15:1591-1599.
58. Thieme S., et al. Stromal cell-derived factor-1alpha-directed chemoattraction of transiently CXCR4-overexpressing bone marrow stromal cells into functionalized three-dimensional biomimetic scaffolds. Tissue Eng. Part C: Methods 2009, 15:687-696.
59. He X., et al. Migration of marrow stromal cells in response to sustained release of stromal-derived factor-1alpha from poly(lactide ethylene oxide fumarate) hydrogels. Int. J. Pharm. 2010, 390:107-116.
60. Kim K., et al. Anatomically shaped tooth and periodontal regeneration by cell homing. J. Dent. Res. 2010, 89:842-847.
61. Kimura Y., Tabata Y. Controlled release of stromal-cell-derived factor-1 from gelatin hydrogels enhances angiogenesis. J. Biomater. Sci. Polym. Ed. 2010, 21:37-51.
62. Rabbany S.Y., et al. Continuous delivery of stromal cell-derived factor-1 from alginate scaffolds accelerates wound healing. Cell Transplant. 2010, 19:399-408.
63. Shen W., et al. The effect of incorporation of exogenous stromal cell-derived factor-1 alpha within a knitted silk-collagen sponge scaffold on tendon regeneration. Biomaterials 2010, 31:7239-7249.
64. Thevenot P.T., et al. The effect of incorporation of SDF-1alpha into PLGA scaffolds on stem cell recruitment and the inflammatory response. Biomaterials 2010, 31:3997-4008.
65. Cross D.P., Wang C. Stromal-derived factor-1 alpha-loaded PLGA microspheres for stem cell recruitment. Pharm. Res. 2011, 28:2477-2489.
66. Kuraitis D., et al. A stromal cell-derived factor-1 releasing matrix enhances the progenitor cell response and blood vessel growth in ischaemic skeletal muscle. Eur. Cell. Mater. 2011, 22:109-123.
67. Ratanavaraporn J., et al. Synergistic effects of the dual release of stromal cell-derived factor-1 and bone morphogenetic protein-2 from hydrogels on bone regeneration. Biomaterials 2011, 32:2797-2811.
68. Sobkow L., et al. Prolonged transendothelial migration of human haematopoietic stem and progenitor cells (HSPCs) towards hydrogel-released SDF1. Ann. Hematol. 2011, 90:865-871.
69. Baumann L., et al. A novel, biased-like SDF-1 derivative acts synergistically with starPEG-based heparin hydrogels and improves eEPC migration in vitro. J. Control. Release 2012, 162:68-75.
70. Goncalves R.M., et al. Mesenchymal stem cell recruitment by stromal derived factor-1-delivery systems based on chitosan/poly(gamma-glutamic acid) polyelectrolyte complexes. Eur. Cell. Mater. 2012, 23:249-260. discussion 260-261.
71. Huang Y.C., Liu T.J. Mobilization of mesenchymal stem cells by stromal cell-derived factor-1 released from chitosan/tripolyphosphate/fucoidan nanoparticles. Acta Biomater. 2012, 8:1048-1056.
72. Ko I.K., et al. Combined systemic and local delivery of stem cell inducing/recruiting factors for in situ tissue regeneration. FASEB J. 2012, 26:158-168.
73. Niu L.N., et al. Intrafibrillar silicification of collagen scaffolds for sustained release of stem cell homing chemokine in hard tissue regeneration. FASEB J. 2012, 26:4517-4529.
74. Prokoph S., et al. Sustained delivery of SDF-1alpha from heparin-based hydrogels to attract circulating pro-angiogenic cells. Biomaterials 2012, 33:4792-4800.
75. Purcell B.P., et al. Synergistic effects of SDF-1alpha chemokine and hyaluronic acid release from degradable hydrogels on directing bone marrow derived cell homing to the myocardium. Biomaterials 2012, 33:7849-7857.
76. Yu J., et al. The effect of stromal cell-derived factor-1alpha/heparin coating of biodegradable vascular grafts on the recruitment of both endothelial and smooth muscle progenitor cells for accelerated regeneration. Biomaterials 2012, 33:8062-8074.
77. Chen F.M., et al. Surface-engineering of glycidyl methacrylated dextran/gelatin microcapsules with thermo-responsive poly(N-isopropylacrylamide) gates for controlled delivery of stromal cell-derived factor-1alpha. Biomaterials 2013, 34:6515-6527.
78. Ji W., et al. Incorporation of stromal cell-derived factor-1alpha in PCL/gelatin electrospun membranes for guided bone regeneration. Biomaterials 2013, 34:735-745.
79. Lim T.C., et al. Chemotactic recruitment of adult neural progenitor cells into multifunctional hydrogels providing sustained SDF-1alpha release and compatible structural support. FASEB J. 2013, 27:1023-1033.
80. MacArthur J.W., et al. Sustained release of engineered stromal cell-derived factor 1-alpha from injectable hydrogels effectively recruits endothelial progenitor cells and preserves ventricular function after myocardial infarction. Circulation 2013, 128:S79-S86.
81. Zhang W., et al. The use of type 1 collagen scaffold containing stromal cell-derived factor-1 to create a matrix environment conducive to partial-thickness cartilage defects repair. Biomaterials 2013, 34:713-723.
82. Dalonneau F., et al. The effect of delivering the chemokine SDF-1alpha in a matrix-bound manner on myogenesis. Biomaterials 2014, 35:4525-4535.
83. Ko C.Y., et al. The use of chemokine-releasing tissue engineering scaffolds in a model of inflammatory response-mediated melanoma cancer metastasis. Biomaterials 2012, 33:876-885.
84. Jay S.M., et al. Dual delivery of VEGF and MCP-1 to support endothelial cell transplantation for therapeutic vascularization. Biomaterials 2010, 31:3054-3062.
85. Fredenberg S., et al. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems - a review. Int. J. Pharm. 2011, 415:34-52.
86. Sadir R., et al. Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J. Biol. Chem. 2004, 279:43854-43860.
87. Shi Y., et al. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol. 2012, 33:136-143.
88. Karp J.M., Leng Teo G.S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009, 4:206-216.
89. Dominici M., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
90. Mendez-Ferrer S., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466:829-834.
91. Caplan A.I. Mesenchymal stem cells. J. Orthop. Res. 1991, 9:641-650.